Toxicities experienced by donors on this study and CIBMTR control group
| . | Plerixafor . | RDSafe . | P . |
|---|---|---|---|
| Number of donors | 64 | 1098 | |
| Number of centers | 12 | 42 | |
| Maximum toxicity at collection, n (%) | <.001 | ||
| 0 | 19 (30) | 188 (17) | |
| 1 | 34 (53) | 411 (38) | |
| 2 | 10 (16) | 328 (30) | |
| 3-4 | 1 (2) | 164 (15) | |
| Maximum toxicity at 1 mo, n (%) | .538 | ||
| 0 | 33 (60) | 520 (54) | |
| 1 | 14 (25) | 308 (32) | |
| 2 | 8 (15) | 111 (11) | |
| 3-4 | 0 | 29 (3) | |
| Recovery at 1 mo, n (%) | |||
| Yes | 43 (67) | 590 (62) | .440 |
| No | 21 (33) | 356 (38) | |
| Unknown | 0 | 152 |
| . | Plerixafor . | RDSafe . | P . |
|---|---|---|---|
| Number of donors | 64 | 1098 | |
| Number of centers | 12 | 42 | |
| Maximum toxicity at collection, n (%) | <.001 | ||
| 0 | 19 (30) | 188 (17) | |
| 1 | 34 (53) | 411 (38) | |
| 2 | 10 (16) | 328 (30) | |
| 3-4 | 1 (2) | 164 (15) | |
| Maximum toxicity at 1 mo, n (%) | .538 | ||
| 0 | 33 (60) | 520 (54) | |
| 1 | 14 (25) | 308 (32) | |
| 2 | 8 (15) | 111 (11) | |
| 3-4 | 0 | 29 (3) | |
| Recovery at 1 mo, n (%) | |||
| Yes | 43 (67) | 590 (62) | .440 |
| No | 21 (33) | 356 (38) | |
| Unknown | 0 | 152 |